Article Text

Download PDFPDF

Will the real Cowden syndrome please stand up (again)? Expanding mutational and clinical spectra of the PTEN hamartoma tumour syndrome
  1. R Pilarski1,
  2. C Eng2,3
  1. 1Clinical Cancer Genetics Program, Comprehensive Cancer Center, Division of Human Genetics, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA
  2. 2Clinical Cancer Genetics Program and Human Cancer Genetics Program, Comprehensive Cancer Center, Division of Human Genetics, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA
  3. 3Cancer Research UK Human Cancer Genetics Research Group, University of Cambridge, UK
  1. Correspondence to:
 Professor C Eng
 Human Cancer Genetics Program, The Ohio State University, 420 W 12th Avenue, Ste 690 TMRF, Columbus, OH 43210, USA;

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

PTEN hamartoma tumour syndrome

Since consensus operational diagnostic criteria for Cowden syndrome (MIM 158350) were first established in 1995, our understanding of this complex disease—and the spectrum of disorders related to it by virtue of also having germline mutations in the PTEN tumour suppressor gene—has continued to evolve. This was reflected in a commentary1 in this journal in 2000 in which it was proposed that endometrial cancer and renal cell carcinoma be added to the operational diagnostic criteria for Cowden syndrome (table 1). This updated commentary is intended to provide a review of significant changes in our understanding of the growing group of disorders, which are known to be caused by germline mutations in PTEN on 10q23.3, and which have been termed the PTEN hamartoma tumour syndrome.

Table 1

International Cowden Consortium operational criteria for the diagnosis of Cowden syndrome. Ver 2000


Cowden syndrome is a complex disorder with malignant and benign (hamartomatous) lesions affecting derivatives of all three germ cell layers. Major organs involved include the breast, thyroid, uterus, brain, and mucocutaneous tissues.2 It has been estimated to affect about 1 in 200 000 individuals,3,4 although this is probably an underestimate given the difficulty in diagnosis presented by this highly variable disease and the fact that many component features in and of themselves can occur in the general population. Penetrance is related to age, with most patients presenting by their late twenties with at least the mucocutaneous lesions of this disorder, which are reportedly seen in 99% of affected individuals. The lifetime risk for breast cancer in Cowden syndrome is estimated to be 25–50%, with an average age of diagnosis between 38 and 46 years old.2,5 The risk for thyroid cancer (typically follicular, but occasionally papillary) is approximately 10%, while the risk for endometrial cancer, although not well established, has been estimated to be 5–10%1,2 (Eng, unpublished observations). Germline mutations in PTEN are associated with Cowden syndrome.6,7 The frequency of germline PTEN mutations in Cowden syndrome probands ascertained by the strict operational diagnostic criteria for Cowden syndrome1,8 was 80%.7 These data demonstrated that the operational clinical diagnostic criteria are robust even at the molecular level. Nonetheless, it became obvious that other types of alterations in PTEN might account for the remainder of Cowden syndrome.

Bannayan-Riley-Ruvalcaba syndrome (MIM 153480) is a congenital disorder characterised by macrocephaly, lipomatosis, haemangiomatosis, and pigmented macules of the glans penis.9 Bannayan-Riley-Ruvalcaba syndrome was shown to be allelic to Cowden syndrome when germline mutations of PTEN were found in approximately 50–60% of individuals with Bannayan-Riley-Ruvalcaba syndrome.10 Supporting this is the fact that identical PTEN mutations have been seen in individuals with Cowden syndrome and with Bannayan-Riley-Ruvalcaba syndrome, and indeed families have been reported in which some affected individuals have Cowden syndrome and others Bannayan-Riley-Ruvalcaba syndrome.10,11 Over 90% of these Cowden syndrome/Bannayan-Riley-Ruvalcaba syndrome overlap families are found to have germline PTEN mutations (Eng, unpublished observations).10 While Bannayan-Riley-Ruvalcaba syndrome has, in the past, not been considered to have increased risks for cancer, the identification of germline mutations in PTEN in over 50% of cases suggests that at least these patients with Bannayan-Riley-Ruvalcaba syndrome should be considered to be at risk for cancers related to Cowden syndrome.

Proteus syndrome (MIM 176920) is a highly variable disorder involving congenital malformations, hamartomatous overgrowth of multiple tissues, connective tissue and epidermal naevi, and hyperostoses which affect patients in a mosaic pattern. Consensus diagnostic criteria have been published.12 While initially thought to be unrelated to Cowden syndrome or Bannayan-Riley-Ruvalcaba syndrome, at least two independent reports have identified germline PTEN mutations in approximately 20% of patients with Proteus syndrome.13,14 Furthermore, approximately 50% of patients with a Proteus-like syndrome (with significant features of Proteus syndrome, but not meeting diagnostic criteria) were also found to have germline PTEN mutations.13 Thus, at least a subset of Proteus syndrome and Proteus syndrome-like conditions are allelic to Cowden syndrome and Bannayan-Riley-Ruvalcaba syndrome, and are part of the PTEN hamartoma tumour syndrome spectrum.

In addition, several reports have now identified PTEN mutations in patients with macrocephaly and autistic features.15,16 At least one child with VATER association and macrocephaly has been found to have a germline PTEN mutation.17 Recently, a child with Bannayan-Riley-Ruvalcaba syndrome-like features and hemimegencephaly was shown to carry a germline PTEN IVS5+1delG mutation.18 However, the true contribution of PTEN mutations to the aetiology of these types of presentation remains to be determined.


Lhermitte-Duclos disease, or dysplastic gangliocytoma of the cerebellum, is a hamartomatous overgrowth believed to be a component feature of Cowden syndrome.19,20 Clinically, patients with Lhermitte-Duclos disease may present with ataxia, increased intracranial pressure, and seizures. Although familial cases are known, Lhermitte-Duclos disease is usually sporadic, and the exact contribution of Cowden syndrome to the overall incidence of Lhermitte-Duclos disease is unknown. In a recent report, PTEN mutations were identified in tissues from Lhermitte-Duclos disease lesions from 15 (83%) of 18 unselected patients.21 Immunostaining also showed reduced or absent PTEN expression in 11(78%) of 14 samples analysed and, more importantly, they were shown to have increased Akt phosphorylation which reflects downstream dysfunction leading to inability to undergo apoptosis and G1 cell cycle arrest.21 All individuals with mutations had adult onset Lhermitte-Duclos disease, while the three patients without mutations had the childhood onset disease. This corroborates two previous reports from the literature in which germline PTEN mutations and signs of Cowden syndrome and Bannayan-Riley-Ruvalcaba syndrome were absent in patients with childhood onset Lhermitte-Duclos disease.22,23 Germline DNA was available from six of the adult patients, and testing confirmed the presence of a germline mutation in each. Two of the six had features of Cowden syndrome, one did not, and three did not have available clinical information. These results confirm that adult onset Lhermitte-Duclos disease is a major component of Cowden syndrome, and that individuals with adult onset Lhermitte-Duclos disease should be evaluated carefully for signs of Cowden syndrome and should routinely be offered PTEN gene testing, even in the absence of other signs of PTEN hamartoma tumour syndrome. While these data are almost compelling to move Lhermitte-Duclos disease to the pathognomonic category in the operational diagnostic criteria, we have left it in the major criteria section for now (table 1).


Promoter and deletion mutations. Germline PTEN mutations have been identified in 80% of individuals meeting diagnostic criteria for Cowden syndrome and in 50–60% of patients with a diagnosis of Bannayan-Riley-Ruvalcaba syndrome, using PCR based mutation analysis of the coding and flanking intronic regions of the gene.7,10 Whether the remaining patients have undetected PTEN mutations or mutations in other, unidentified, genes is not definitively known, although it is believed that Cowden syndrome is not genetically heterogeneous.8 Scanning the 600 base pair full promoter region has recently revealed germline PTEN promoter mutations in 9 (≈10%) of 95 Cowden syndrome patients who had previously been found to be mutation negative on testing of the coding and flanking intronic regions.24 None of these mutations were found among 372 control alleles studied. All nine patients had breast cancer or benign breast disease, or both, but otherwise relatively few other organs were involved. Protein lysates from peripheral blood lymphoblastoid cells from five of these nine patients were found to have decreased levels of normal PTEN protein and concordant increase or laddering of alternate bands on western blotting which were not observed in 32 control samples or 23 mutation negative samples. Reflecting PTEN dysfunction, germline protein from individuals with promoter mutations had increased phosphorylated Akt. Further, large germline PTEN deletions encompassing all or part of the gene were noted in 3 (11%) of 27 Bannayan-Riley-Ruvalcaba syndrome patients studied (two Bannayan-Riley-Ruvalcaba syndrome; one Bannayan-Riley-Ruvalcaba syndrome/Cowden syndrome overlap). Protein analysis from one of these patients found a 50% decrease in PTEN protein level and concomitant increase in phosphorylated Akt.

Of note, only Cowden syndrome probands were found to harbour germline PTEN promoter mutations.24 No promoter mutations have been found in Bannayan-Riley-Ruvalcaba syndrome to date although the work is ongoing. In contrast, only Bannayan-Riley-Ruvalcaba syndrome (or Cowden syndrome/Bannayan-Riley-Ruvalcaba syndrome overlap) patients have been found to have large deletions or rearrangements involving PTEN.10,24,25

Finally, a de novo case of Cowden syndrome presenting with Lhermitte-Duclos disease in adulthood was found to have the de novo germline PTEN mutation c.179delA arise on the paternal chromosome.26 Whether the majority of cases of Cowden syndrome, Bannayan-Riley-Ruvalcaba syndrome, and PTEN hamartoma tumour syndrome arise on paternal chromosomes is unknown and is a question which needs to be investigated.


Management for Cowden syndrome is primarily focused on the cancer risks. Clinical breast examinations are recommended annually for women beginning at age 25, and annual mammography starting at age 30–35. Breast cancer has been reported in men with Cowden syndrome, and it is thus recommended that they practise regular breast self examinations. Men and women should have an annual physical examination beginning at age 18, with careful attention paid to the skin and neck region. A baseline thyroid ultrasound is also recommended at age 18 (with consideration of annual thyroid ultrasound thereafter). Women with Cowden syndrome should also undergo endometrial screening involving annual blind (repel) biopsies starting at age 35–40, and annual endometrial ultrasound after menopause, with biopsy of suspicious lesions. Annual urine analysis for the detection of renal cell carcinoma is also recommended along with annual urine cytology and renal ultrasound if there is a family history of renal cancer.27

While cancer risks in Bannayan-Riley-Ruvalcaba syndrome were initially felt to be similar to those of the general population, confirmation that >60% of Bannayan-Riley-Ruvalcaba syndrome is allelic to Cowden syndrome and due to PTEN gene mutations has led to the recommendation that Bannayan-Riley-Ruvalcaba syndrome patients should conservatively be managed according to Cowden syndrome guidelines. While the gastrointestinal hamartomatous polyposis seen in Bannayan-Riley-Ruvalcaba syndrome does not predispose to significantly increased cancer risks, patients should be monitored for complications of the polyps themselves, such as intussusception.

It has only recently been shown that a subset of patients with Proteus syndrome and Proteus-like syndrome have PTEN mutations, and at this point it is not clear whether cancer risks associated with Cowden syndrome pertain to these patients as well. To be conservative, it might be prudent to follow Cowden syndrome screening guidelines for patients with PTEN mutation positive Proteus syndrome and Proteus-like syndrome as well.


The recent identification of germline PTEN deletions and promoter mutations indicates that these types of mutation account for approximately 10% each of patients with Cowden syndrome and patients with Bannayan-Riley-Ruvalcaba syndrome who are mutation-negative on PCR based analysis, even using direct sequencing, of exons 1–9 and flanking intronic regions. Thus, all in all, the germline PTEN mutation frequencies for Cowden syndrome and Bannayan-Riley-Ruvalcaba syndrome would approach 85–90% and 65%, respectively. Because promoter mutations have only been noted in Cowden syndrome up until now, it is possible that promoter analysis should be limited to Cowden syndrome. Similarly, should large deletions continue to be observed only in Bannayan-Riley-Ruvalcaba syndrome or Cowden syndrome/Bannayan-Riley-Ruvalcaba syndrome overlap, and not Cowden syndrome, perhaps deletion analysis should only be offered in Bannayan-Riley-Ruvalcaba syndrome.

In addition to being aetiologic for classic Cowden syndrome and Bannayan-Riley-Ruvalcaba syndrome, germline PTEN mutations are being shown to be responsible for an increasing spectrum of clinical disorders. PTEN mutations, which are responsible for the majority of cases of Cowden syndrome and Bannayan-Riley-Ruvalcaba syndrome, have now been clearly shown to contribute to a subset of cases of Proteus syndrome and Proteus-like syndrome. In addition, germline PTEN mutations may account for the majority of patients with adult onset Lhermitte-Duclos disease, with or without the presence of other signs of Cowden syndrome in the patient. Thus, PTEN gene testing may be indicated in all cases of adult onset Lhermitte-Duclos disease. The contribution of PTEN mutations to cases with both macrocephaly and autism remains open to investigation, as do other aspects of this fascinating and evolving spectrum of disorders.


We would like to thank the patients and families who have participated in our studies, and past and present members of the Eng laboratory, collaborators, colleagues, and genetic counsellors who have also contributed, in one way or another, to our research.

PTEN hamartoma tumour syndrome